PROT Stock Overview

A biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. More details

PROT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap ($7)

Latest financial reports are more than a year old

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Proteonomix, Inc. Competitors

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

DermTech

OTCPK:DMTK.Q

US$35.0

Price History & Performance

Summary of share price highs, lows and changes for Proteonomix
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	0%
5 Year Change	-99.99%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PROT	US Biotechs	US Market
7D	0%	-0.2%	3.2%
1Y	n/a	-6.9%	24.0%

Return vs Industry: Insufficient data to determine how PROT performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PROT performed against the US Market.

Price Volatility

Is PROT's price volatile compared to industry and market?
PROT volatility
PROT Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.1%
Market Average Movement	6.5%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: PROT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PROT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1995	n/a	Michael Cohen	www.proteonomix.com

Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles.

Proteonomix, Inc. Fundamentals Summary

How do Proteonomix's earnings and revenue compare to its market cap?
PROT fundamental statistics
Market cap	US$7.00
Earnings (TTM)	-US$672.05k
Revenue (TTM)	US$26.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is PROT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PROT income statement (TTM)
Revenue	US$26.00k
Cost of Revenue	-US$513.00
Gross Profit	US$26.52k
Other Expenses	US$698.57k
Earnings	-US$672.05k

Last Reported Earnings

Jun 30, 2012

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did PROT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/18 06:51
End of Day Share Price	2024/12/27 00:00
Earnings	2012/06/30
Annual Earnings	2011/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Proteonomix, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution